Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued
Reference number: GID-TA10427
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease.
For information and following advice received from the company, the appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease [ID1420] has now been suspended. This is because the Scleroderma-associated interstitial lung disease (SSc-ILD) population for ID1420 will now be covered within the licence for the appraisal for nintedanib for treating progressive fibrosing interstitial lung disease [ID1599].
For further information on the timelines for ID1599 please see the following link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10520